Although mutations in ras represent but one of a multitude of genetic events required for conversion of normal cells to the fully malignant state, aberrant upregulation of Ras function causes multiple aspects of the abnormal biology of cancer cells. We propose studies to achieve two broad goals. First, we will delineate the signaling pathways that mediate oncogenic Ras deregulation of the expression of specific genes. Second, we will assess how the products of these genes contribute to malignant transformation of epithelial cells. Specifically, we will evaluate the aberrant action of genes that deregulate progression through the G1 phase of the cell cycle (cyclin DI, p21, and p27), anchorage-independent growth, tumor angiogenesis (VEGF), invasion, and metastasis (MMP-9). Representational difference analysis has also been applied to identify additional gene targets important for Ras oncogenesis. Our rationale for these studies is shaped by recent revelations that Ras signaling is much more complex than simply activating the Raf/MEK/ERK kinase cascade and that cell type differences exist concerning how Ras causes transformation. Our working hypothesis is that, contrary to the """"""""dogma"""""""" established in NIH 3T3 mouse fibroblast studies, oncogenic Ras transformation of epithelial cells is highly dependent on signaling pathways distinct from the Raf/MEK/ERK pathway. The Raf/MEK/ERK cascade has been targeted for the development of anti-Ras drugs for cancer treatment. Since the majority of ras mutations occur in human cancers derived from epithelial cells, an assessment of the relative contribution of Raf-dependent and Raf-independent pathways to Ras transformation of epithelial cells is of obvious importance. Our studies may refocus future efforts to target other Ras signaling pathways for the development of novel therapeutic agents for cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA042978-14
Application #
6043252
Study Section
Pathology B Study Section (PTHB)
Program Officer
Jhappan, Chamelli
Project Start
1986-07-01
Project End
2004-11-30
Budget Start
2000-01-01
Budget End
2000-11-30
Support Year
14
Fiscal Year
2000
Total Cost
$323,994
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Waters, Andrew M; Der, Channing J (2018) KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. Cold Spring Harb Perspect Med 8:
Vaseva, Angelina V; Blake, Devon R; Gilbert, Thomas S K et al. (2018) KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell 34:807-822.e7
Papke, Bjoern; Der, Channing J (2017) Drugging RAS: Know the enemy. Science 355:1158-1163
Waters, Andrew M; Ozkan-Dagliyan, Irem; Vaseva, Angelina V et al. (2017) Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Sci Signal 10:
Yin, Guowei; Kistler, Samantha; George, Samuel D et al. (2017) A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation. J Biol Chem 292:4446-4456
Justilien, Verline; Ali, Syed A; Jamieson, Lee et al. (2017) Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma. Cancer Cell 31:256-269
Lawson, Campbell D; Fan, Cheng; Mitin, Natalia et al. (2016) Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. Cancer Res 76:3826-37
Gentry, Leanna R; Karginov, Andrei V; Hahn, Klaus M et al. (2016) Characterization of an Engineered Src Kinase to Study Src Signaling and Biology. Methods Mol Biol 1360:157-67
Zhou, Bingying; Ritt, Daniel A; Morrison, Deborah K et al. (2016) Protein Kinase CK2? Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2? Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. J Biol Chem 291:17804-15
Hobbs, G Aaron; Der, Channing J; Rossman, Kent L (2016) RAS isoforms and mutations in cancer at a glance. J Cell Sci 129:1287-92

Showing the most recent 10 out of 169 publications